The Global Paricalcitol Market is estimated to grow at a significant CAGR during the forecast period. Paricalcitol is a synthesised (man-made) version of vitamin D. Calcium absorption from the stomach and calcium function in the body both require vitamin D. Paricalcitol is used to treat and prevent hyperparathyroidism in dialysis patients with chronic renal disease. Hyperparathyroidism is a condition in which the parathyroid glands in the neck overproduce parathyroid hormone (PTH).
This hormone regulates the calcium and phosphorus levels in your blood. Paricalcitol aids in the reduction of PTH, which reduces calcium and phosphorus levels. For the treatment of post-transplantation osteoporosis or in patients with chronic kidney diseases as well as vitamin D deficiency, Paricalcitol is used. Factors such as the rising incidence of chronic renal disease and the rising number of patients with secondary hyperparathyroidism might be attributed to the market's expansion.
The Paricalcitol medication has been approved by the FDA for use in adults with stage 3 or 4 chronic renal disease who are on dialysis or have a creatinine clearance of less than 30 mL/min, as well as people with secondary hyperparathyroidism who are on dialysis (high levels of parathyroid hormone). Paricalcitol can be given intravenously or orally, depending on the patient's condition and preference; it can also be given as a monthly injection under the skin (subcutaneously).
Market Coverage
o By Type
o By Application
o North America
o Europe
o Asia-Pacific
o Rest of the world
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Paricalcitol Market by Segments,
By Type:
By Application:
Global Paricalcitol Market by Region
North America
Europe
Asia-Pacific
Rest of the World